Jared Gollob

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

David Adams, Alejandra González‐Duarte, William O’Riordan et al. · New England Journal of Medicine · 2018 · 2.9K citations · Full text

Life Sciences, Molecular Biology, Pharmacology +14

Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis

Teresa Coelho, David Adams, Ana Silva et al. · New England Journal of Medicine · 2013 · 961 citations · Full text

Life Sciences, Molecular Biology, Molecular Medicine +15

Impairment of Mycobacterial Immunity in Human Interleukin-12 Receptor Deficiency

Frédéric Altare, Anne Durandy, David A. Lammas et al. · Science · 1998 · 840 citations

Veterinary Medicine, Immunology, Microbiology +17

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

David F. McDermott, Meredith M. Regan, Joseph I. Clark et al. · Journal of Clinical Oncology · 2004 · 819 citations

Medicine, Oncology, Pharmacotherapy +15

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Josep Tabernero, Geoffrey I. Shapiro, Patricia LoRusso et al. · Cancer Discovery · 2013 · 699 citations

Pharmacy, Oncology, Pharmaceutics +17